Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

404 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Recurrent Streptococcus mutans endocarditis.
Vose JM, Smith PW, Henry M, Colan D. Vose JM, et al. Am J Med. 1987 Mar 23;82(3 Spec No):630-2. doi: 10.1016/0002-9343(87)90111-2. Am J Med. 1987. PMID: 3826124
Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease.
Armitage JO, Bierman PJ, Vose JM, Anderson JR, Weisenburger DD, Kessinger A, Reed EC, Vaughan WP, Coccia PF, Purtilo DT. Armitage JO, et al. Am J Med. 1991 Dec;91(6):605-11. doi: 10.1016/0002-9343(91)90213-h. Am J Med. 1991. PMID: 1750430
Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation.
Vose JM, Armitage JO, Bierman PJ, Weisenburger DD, Hutchins M, Dowling MD, Moravec DF, Sorensen S, Okerbloom J, Bascom G, et al. Vose JM, et al. Am J Med. 1989 Sep;87(3):285-8. doi: 10.1016/s0002-9343(89)80152-4. Am J Med. 1989. PMID: 2672808
Intensified chemotherapy for diffuse large B-cell lymphomas.
Vose JM. Vose JM. Lancet. 2011 Nov 26;378(9806):1828-9. doi: 10.1016/S0140-6736(11)61269-5. Lancet. 2011. PMID: 22118432 No abstract available.
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP. Friedberg JW, et al. Blood. 2011 Mar 10;117(10):2807-12. doi: 10.1182/blood-2010-11-314708. Epub 2011 Jan 14. Blood. 2011. PMID: 21239695 Free PMC article. Clinical Trial.
Ten years of progress in the treatment of Non-Hodgkin's Lymphoma.
Vose JM. Vose JM. J Natl Compr Canc Netw. 2013 Jan 1;11(1):3-4. doi: 10.6004/jnccn.2013.0002. J Natl Compr Canc Netw. 2013. PMID: 23307975 No abstract available.
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics.
Casulo C, Vose JM, Ho WY, Kahl B, Brunvand M, Goy A, Kasamon Y, Cheson B, Friedberg JW. Casulo C, et al. Clin Immunol. 2014 Sep;154(1):37-46. doi: 10.1016/j.clim.2014.06.005. Epub 2014 Jun 11. Clin Immunol. 2014. PMID: 24928323 Free PMC article. Clinical Trial.
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM. Witzig TE, et al. J Clin Oncol. 2009 Nov 10;27(32):5404-9. doi: 10.1200/JCO.2008.21.1169. Epub 2009 Oct 5. J Clin Oncol. 2009. PMID: 19805688 Clinical Trial.
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM. Wiernik PH, et al. J Clin Oncol. 2008 Oct 20;26(30):4952-7. doi: 10.1200/JCO.2007.15.3429. Epub 2008 Jul 7. J Clin Oncol. 2008. PMID: 18606983 Clinical Trial.
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD. Juweid ME, et al. J Clin Oncol. 2005 Jul 20;23(21):4652-61. doi: 10.1200/JCO.2005.01.891. Epub 2005 Apr 18. J Clin Oncol. 2005. PMID: 15837965
404 results
Jump to page
Feedback